Noncompartmental determination of the steady-state volume of distribution.

In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother (1984) 3.66

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother (1992) 2.93

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 2.73

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother (1987) 1.94

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88

Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans. Antimicrob Agents Chemother (1988) 1.64

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother (1992) 1.53

Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41

Pharmacokinetics of rifabutin. Antimicrob Agents Chemother (1989) 1.30

Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics (2012) 1.29

Pharmacokinetics of mecillinam in health subjects. Antimicrob Agents Chemother (1980) 1.28

Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother (1986) 1.23

Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrob Agents Chemother (1985) 1.20

Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol (1986) 1.20

Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1982) 1.20

Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol (2001) 1.17

Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob Agents Chemother (1984) 1.16

Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol (1984) 1.01

Pharmacokinetics and molecular detoxication. Environ Health Perspect (1996) 1.01

Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother (1996) 1.00

Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer (1994) 0.98

Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. Br J Clin Pharmacol (1985) 0.98

Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol (1986) 0.97

Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. Br J Clin Pharmacol (1986) 0.96

Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother (2011) 0.96

Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. Br J Clin Pharmacol (1984) 0.95

Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother (1992) 0.95

Cimetidine does not alter morphine disposition in man. Br J Clin Pharmacol (1982) 0.94

Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci (2003) 0.94

Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics. Antimicrob Agents Chemother (1985) 0.93

Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc Nephrol (2011) 0.93

Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys. Antimicrob Agents Chemother (1987) 0.93

Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol (1984) 0.92

Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. Br J Clin Pharmacol (1985) 0.92

The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone. Br J Clin Pharmacol (1986) 0.92

Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics. Antimicrob Agents Chemother (1986) 0.91

Multiple-dose pharmacokinetics of amdinocillin in healthy volunteers. Antimicrob Agents Chemother (1982) 0.91

Cefoperazone pharmacokinetics in preterm infants. Antimicrob Agents Chemother (1983) 0.89

The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study. Br J Pharmacol (2002) 0.89

Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol (1985) 0.86

Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrob Agents Chemother (1993) 0.86

Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Antimicrob Agents Chemother (1986) 0.85

The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol (1985) 0.85

Clearance (née Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn (2010) 0.85

Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol (1983) 0.85

Effect of age and renal function on cefonicid pharmacokinetics. Antimicrob Agents Chemother (1989) 0.83

Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol (1983) 0.83

Effect of pirprofen on glibenclamide kinetics and response. Br J Clin Pharmacol (1982) 0.83

Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother (1988) 0.83

The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. Br J Clin Pharmacol (1994) 0.83

Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers. Antimicrob Agents Chemother (1990) 0.82

Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1988) 0.81

A low-protein diet restricts albumin synthesis in nephrotic rats. J Clin Invest (1989) 0.81

Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol (1995) 0.79

Ranitidine disposition in patients with renal impairment. Br J Clin Pharmacol (1983) 0.79

Intra and interindividual variability in the kinetics of a poorly and highly metabolising solvent. Br J Ind Med (1989) 0.79

Cimetidine alters pethidine disposition in man. Br J Clin Pharmacol (1984) 0.79

Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. Antimicrob Agents Chemother (1994) 0.79

Pharmacokinetics and biliary excretion of bromosulphophthalein, [3H]-ouabain and [3H]-taurocholic acid in rats with glycerol-induced acute renal failure. Br J Pharmacol (1984) 0.78

Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections. PLoS One (2016) 0.78

Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. Br J Clin Pharmacol (1982) 0.78

Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition. Br J Clin Pharmacol (1987) 0.77

Lack of effect of tenoxicam on glibornuride kinetics and response. Br J Clin Pharmacol (1985) 0.77

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial. Br J Cancer (1987) 0.77

Ranitidine does not alter pethidine disposition in man. Br J Clin Pharmacol (1985) 0.75

Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. Antimicrob Agents Chemother (1995) 0.75

Alcuronium kinetics in patients undergoing cardiopulmonary bypass surgery. Br J Clin Pharmacol (1983) 0.75

Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (1987) 0.75

Mexiletine disposition: individual variation in response to urine acidification and alkalinisation. Br J Clin Pharmacol (1983) 0.75

Benet L Z and Galeazzi R L: noncompartmental determination of the steady-state volume of distribution, J Pharm Sci 68, 1071-1074, 1979--the backstory. AAPS J (2012) 0.75

The effect of ranitidine on the disposition of lignocaine. Br J Clin Pharmacol (1985) 0.75

Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1986) 0.75

Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. Antimicrob Agents Chemother (2013) 0.75

Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose. Antimicrob Agents Chemother (2000) 0.75

HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50

Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther (2012) 2.38

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog (1995) 2.25

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther (1997) 2.17

Pharmacokinetics of phenylethylacetylurea (pheneturide), an old antiepileptic drug. J Pharmacokinet Biopharm (1979) 2.16

Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm (1973) 2.16

Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther (1976) 2.08

Gender effects in pharmacokinetics and pharmacodynamics. Drugs (1995) 1.94

Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82

The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet (2001) 1.72

Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant (2007) 1.69

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther (2006) 1.69

Sudden death in cancer patient on high-dose domperidone. Lancet (1982) 1.60

Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J Biol Chem (1998) 1.58

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther (1997) 1.55

Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology (1992) 1.53

Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm (1980) 1.50

Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm (1979) 1.47

Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm (1978) 1.44

Application of clearance concepts to the assessment of exposure to lead in drinking water. Am J Public Health (1989) 1.43

Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos (2000) 1.40

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci (1998) 1.37

Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev (1992) 1.32

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther (1995) 1.28

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther (1995) 1.25

Simultaneous modeling of bopindolol kinetics and dynamics. Clin Pharmacol Ther (1984) 1.22

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol (1996) 1.20

Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev (2001) 1.20

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther (1992) 1.19

Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl (2000) 1.18

Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation. J Pharmacokinet Biopharm (1979) 1.17

Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res (1996) 1.17

Pharmacokinetics of cefamandole using a HPLC assay. J Pharmacokinet Biopharm (1978) 1.15

Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm (1989) 1.15

Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther (2008) 1.14

Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma. Clin Chem (1979) 1.13

Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol (1983) 1.13

Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen, 3'-hydroxyacetanilide, in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol (2001) 1.12

Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references. J Pharmacokinet Biopharm (1975) 1.10

Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol (1995) 1.10

Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos (1999) 1.09

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther (2001) 1.09

Rate of drug metabolism in man measured by 14CO2-breath analysis. Eur J Clin Pharmacol (1978) 1.08

In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos (2000) 1.06

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc (2001) 1.06

Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ (1999) 1.04

General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci (1972) 1.04

Brucellosis: an occupational hazard for medical laboratory personnel. Report of five cases. Infection (1994) 1.01

Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. Transplantation (1982) 1.00

The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther (1977) 1.00

Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther (1998) 1.00

Steady-state concentration of cotinine as a measure of nicotine-intake by smokers. Eur J Clin Pharmacol (1985) 1.00

Incomplete and delayed bioavailability of sublingual nitroglycerin. Am J Cardiol (1985) 0.99

Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med (1979) 0.99

Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther (2007) 0.99

Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res (1999) 0.99

Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol (2001) 0.98

Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther (1977) 0.98

Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos (1999) 0.98

[Rhodococcus erythropolis infection in HIV-associated immunodeficiency]. Schweiz Med Wochenschr (1991) 0.98

Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration. Clin Pharmacol Ther (1987) 0.98

Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm (1980) 0.97

Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. J Chromatogr (1992) 0.96

Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm (1980) 0.96

The bioavailability of oral nitroglycerin. J Pharm Sci (1986) 0.96

General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm (1988) 0.95

Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res (1989) 0.95

Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther (1980) 0.94

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol (1994) 0.94

Obligations of a major professor to a graduate student. Am J Pharm Educ (1977) 0.94

Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. J Pharmacokinet Biopharm (1985) 0.94

Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol (1996) 0.93

Relapsing Whipple's disease presenting with hypopituitarism. Clin Endocrinol (Oxf) (1999) 0.93

Stability of acyl glucuronides in blood, plasma, and urine: studies with zomepirac. Drug Metab Dispos (1985) 0.93

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther (1992) 0.93

The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther (1996) 0.93

Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther (1985) 0.93

Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther (1998) 0.92

High-fat meals increase the clearance of cyclosporine. Pharm Res (1990) 0.92

Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol (2000) 0.91

Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. Clin Pharmacol Ther (1990) 0.91

Disposition and irreversible plasma protein binding of tolmetin in humans. Clin Pharmacol Ther (1988) 0.91

Potentiometric determination of dissociation constants. J Pharm Sci (1967) 0.91

Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther (2010) 0.90

Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1988) 0.89

Glutathione S-transferase-mediated metabolism of glyceryl trinitrate in subcellular fractions of bovine coronary arteries. Pharm Res (1992) 0.89

Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol (1990) 0.88

Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci U S A (1993) 0.88

High-performance liquid chromatographic method for the determination of indomethacin and its two primary metabolites in urine. J Chromatogr (1984) 0.88

Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis (1986) 0.88

Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharm Drug Dispos (1989) 0.87

The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther (1996) 0.87

Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol (1998) 0.87

Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit (2000) 0.86

Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos (1995) 0.86

Interpretation of plasma concentration-time curves after oral dosing. J Pharm Sci (1977) 0.86

Prednisolone clearance at steady state in man. J Clin Endocrinol Metab (1982) 0.86

Pharmacokinetics of triamterene and its metabolite in man. J Pharmacokinet Biopharm (1982) 0.86

Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther (2010) 0.85